VISEN Pharmaceuticals (HK:2561)
:2561
Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$19.16 - HK$54.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.32B
Enterprise ValueHK$1.70B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ResilienceReported low-to-moderate leverage gives the company structural financial flexibility. Even with operating losses, a relatively healthier balance sheet reduces near-term insolvency risk and improves ability to raise incremental financing or negotiate terms over the next several months.
Positive Gross ProfitPositive gross profit indicates the core manufacturing or product economics generate margin. That structural margin underpins potential operating leverage if SG&A and R&D spending are controlled or revenues stabilize, supporting a durable path to improved operating performance.
Improving Free Cash Flow TrendAn improvement in free cash flow growth, even from a negative base, suggests operations or investment timing may be shifting to lower cash burn. If sustained, this trend reduces reliance on external funding and is a durable signal of improving cash conversion over coming quarters.
Bears Say
Persistent Large LossesSustained, very large operating and net losses undermine equity and the company's ability to self-fund growth. Over a multi-quarter horizon this erodes financial flexibility, limits reinvestment capacity, and raises the likelihood of continued external financing or dilution.
Chronic Cash BurnConsistently negative operating and free cash flow create a structural cash burn that must be covered by financing. This persistent outflow limits runway, increases refinancing need, and constrains strategic options like commercialization or larger R&D programs over the medium term.
Rising Debt And Funding RiskA material increase in debt in 2025 raises fixed obligations and refinancing risk. Combined with ongoing losses and cash burn, higher leverage narrows flexibility, can trigger tighter covenants or higher funding costs, and increases solvency risk if operational improvement lags.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$19.16 and its highest was HK$54.00 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.32B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―